FIRST TRACKS BIOTHERAPEUTICS INC (TRAX)
Health Care · Clinical-stage antibody therapeutics · NASDAQ
Clinical-stage antibody-focused biotech advancing immune-modulating therapies for autoimmune and inflammatory diseases including celiac disease, eosinophilic esophagitis, and rheumatoid arthritis.
What FIRST TRACKS BIOTHERAPEUTICS INC does
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapies that modulate immune pathways for autoimmune and inflammatory diseases. The company's pipeline includes ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis; and ANB101, a BDCA2 modulator.
Themes: Autoimmune/inflammatory disease therapy, Antibody therapeutics, Celiac disease, Eosinophilic esophagitis, Rheumatoid arthritis
Fundamentals
- Price$43.11 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-21
- P/En/a earnings data not available
- ROE-57.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.38 as of 2026-08-24
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How TRAX compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How FIRST TRACKS BIOTHERAPEUTICS INC looks technically
FIRST TRACKS BIOTHERAPEUTICS INC (TRAX): a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 50, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 10 trading days ago. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $33.05 | $33.05 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 19.71. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 50, with buyers in control | 49.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 55.3 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($40.72 to $49.91) — its "stochastic" reading is 26 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 26.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $49.91 | $49.91 |
|---|---|---|
| From the 52-week high | it is 13.6% below its 52-week high (its highest price of the past year) | -13.6% |
| Above the 52-week low | it is 191.5% above its 52-week low (its lowest price of the past year) | +191.5% |
| Below the 52-week high | it is 13.6% below its highest point of the past year | 13.6% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $49.91 (set on 2026-08-11) | $49.91 |
| Given back of the 52-week move | not available for this company yet | n/a |
| From the all-time high | it is 13.6% below its all-time high | -13.6% |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $14.79 (set on 2026-04-20) | $14.79 |
| Above the all-time low | it is 191.5% above its all-time low | +191.5% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move | 7th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $3.48 between its high and its low — about 8.1% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $3.48 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $40.88 and $48.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $40.88 – $44.71 – $48.54 |
| Typical daily range (% of price) | its price moves about 8.1% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.1% |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.68× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 24.9% since the prior reading | +24.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 2.6% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +2.6% |
|---|---|---|
| Open gap | it gapped 22.1% above the previous close 19 sessions ago and has not traded back through the level it left behind at 35.52 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +22.1% |
| Gap filled | a 2.6% gap up opened on 2026-08-21 has been "filled" today — price traded back through the level the gap left behind, and it closed again during the very session that opened it | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 13.0 percentage points (the stock gained 15.4% while the market gained 2.3%) | +13.0% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 154.1 percentage points (the stock gained 157.2% while the market gained 3.1%) | +154.1% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 5 technical signals we can compute for it is currently in a bullish state: a strong uptrend, with buyers in control — these describe past price behaviour, not a forecast | 1 of 5 |
|---|---|---|
| Bearish technical signals | 1 of the 5 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 5 |
Volume-weighted price
1
| Vs this year’s average price paid | the price is 46% above the average price paid since 2026-04-20, so the typical buyer over that stretch is showing a gain. That average is $29.48 — a volume-weighted average of daily closes over 77 sessions, not a true tick-by-tick VWAP. | +46.2% |
|---|
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $19.71.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $32.80 and $41.83 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $49.91.
This reading has stood for 4 trading days, since 2026-08-18.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · Printed a doji candle · Most volatile (6%+ typical daily range) · Elliott wave 4 pullbacks | Learn: adx · rsi · breakout · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.38 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$63.38 range $30.00 – $95.00; median $65.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TRAX
- Consensus EPS estimate-$0.8669 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical development and regulatory approval risk: company's pipeline programs are in clinical development stages with uncertain timelines and regulatory outcomes.","Funding requirement risk: company may require additional financing or strategic investments to continue operations, with no assurance such funding will be available on acceptable terms.","Cash burn and liquidity risk: the company is pre-revenue with quarterly operating losses exceeding $50 million and declining cash reserves, requiring operational sustainability within available resources."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days0 buys · 1 sell ($65M) — 1 selling insider
Most recent open-market transaction: 2026-04-20. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TRAX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
TRAX had 3,957,023 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TRAX had 11.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.63 days to cover at the same settlement.
- Reported short interest (shares) 3,957,023
- Short interest (% of shares outstanding) 11.1%
- Prior settlement (shares) 4,771,705
- Reported change -17.07%
- Days to cover (reported) 4.63
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) do?
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapies that modulate immune pathways for autoimmune and inflammatory diseases. The company's pipeline includes ANB033, a CD122 antagonist for celiac disease and eosinophilic esophagitis; rosnilimab, a pathogenic T cell depleter for rheumatoid arthritis; and ANB101, a BDCA2 modulator.
What sector is FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) in?
FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) is classified in the Health Care sector. Its industry is Clinical-stage antibody therapeutics. It trades on NASDAQ.
Is FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) overbought or oversold right now?
FIRST TRACKS BIOTHERAPEUTICS INC (TRAX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TRAX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.